A novel MYD88 mutation, L265RPP, in Waldenström macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival-Reference-Cited by-同舟云学术

A novel MYD88 mutation, L265RPP, in Waldenström macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival

Published:2015-05 Issue:5 Volume:5 Page:e314-e314
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Nagao T,Oshikawa G,Ishida S,Akiyama H,Umezawa Y,Nogami A,Kurosu T,Miura O

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/bcj201536.pdf

Reference14 articles.

1. Rossi D . Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis. Hematology Am Soc Hematol Educ Program 2014; 2014: 113–118.

2. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia. N Engl J Med 2012; 367: 826–833.

3. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115–119.

4. Hunter Z, Xu L, Yang G, Zhou Y, Liu X, Cao Y et al. The genomic landscape of Waldenstom’s macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2013; 123: 1637–1646.

5. Jimenez C, Sebastian E, Chillon MC, Giraldo P, Mariano Hernandez J, Escalante F et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom’s macroglobulinemia. Leukemia 2013; 27: 1722–1728.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies;International Journal of Molecular Sciences;2022-09-22

2. Successful treatment with bortezomib for refractory fever associated with myelodysplastic syndrome with underlying lymphoplasmacytic lymphoma;Clinical Case Reports;2022-02

3. Detection of c.755T>C; p.L265P/c.751C>T;p.264R/* compound heterozygous MYD88 mutation in a case of Waldenstrom macroglobulinemia;Indian Journal of Hematology and Blood Transfusion;2021-05-20

4. Bruton's Tyrosine Kinase Inhibitors for the Treatment of Waldenström's Macroglobulinaemia: A Canadian Perspective;Oncology & Haematology;2021

5. Monitoring of MYD88 L265P mutation by droplet digital polymerase chain reaction for prediction of early relapse in a patient with Bing–Neel syndrome;International Journal of Hematology;2020-11-22